Reduced-Dose Radiation for HPV Throat Cancer Holds Up at 5 Years in 276-Patient Study

Cutting radiation to healthy-looking lymph nodes did not cost patients their cure in a long-term study of HPV-positive oropharyngeal cancer.

Nancy Y. Lee, MD, of Memorial Sloan Kettering Cancer Center and colleagues reported the results in JAMA Oncology. The study followed 276 patients treated with definitive concurrent chemoradiation for a median of five years.

What the numbers show

At last follow-up, 260 patients had no evidence of disease (94%) and 250 were alive (90.6%).

Five-year locoregional control was 97.0%. Distant metastasis-free survival was 91.2%, overall survival 90.8% and progression-free survival 85.9%. Each measures something different.

Distant-only recurrences occurred in 23 patients. Apart from one locoregional failure, recurrences were in areas with known residual macroscopic disease.

The authors reported no failures in the nodal basins that were deliberately left out of treatment. One elective nodal failure occurred in a contralateral lymph node that had been indeterminate on imaging at baseline and had received 30 Gy.

What was actually reduced

Elective nodal irradiation, or ENI, treats lymph-node regions considered at risk even when no cancer is visible there. The usual dose is 50 to 60 Gy.

This regimen gave 30 Gy in 15 fractions to those regions, followed by a sequential 40-Gy boost to areas needing more. It also omitted selected low-risk nodal basins, specifically levels IB and V when uninvolved. Most patients received intensity-modulated radiotherapy. Twenty received intensity-modulated proton therapy.

The authors wrote that omitting those levels "did not result in failures in those areas and provides a simple class solution to reducing irradiated volume and toxic effects." They also said the 30-Gy dose is the lowest among published approaches and produced "the lowest reported gastrostomy tube insertion rate."

They stressed that chemotherapy stayed in the plan. Recent phase III randomized trials, they noted, showed concurrent platinum-based chemotherapy is superior for curing HPV-associated disease. Most patients here received it.

Why dose to healthy tissue matters

David Sher, MD, of UT Southwestern Medical Center in Dallas, was not involved in the work. Speaking as an expert for the American Society for Radiation Oncology, he told MedPage Today that doctors tend to focus on the dose delivered to visible cancer.

"In actuality, ENI is responsible for a substantial amount of normal tissue irradiation and dose to critical normal structures, such as the salivary glands and swallowing structures," Sher said.

He called the degree of success "remarkable given the extent of dose reduction." He added that earlier studies, prospective and retrospective, have shown the standard 50-Gy dose can be substantially lowered.

The gap in the evidence

Sher also said plainly what the study does not contain: "we do not have quality-of-life data from this study." He said prior reports were "also very favorable."

The whole point of de-escalation is fewer long-term side effects, such as dry mouth and trouble swallowing. These results show long-term cancer outcomes. They do not directly measure how patients felt or functioned afterward.

An expert not involved in the study has said confirmation in a multicenter phase III trial is still needed before this becomes standard care.

One patient's version of the stakes

Treatment for aggressive throat cancer carries a real human cost. Poison drummer Rikki Rockett, now 65, told Fox News Digital he has been cancer-free for a decade after a 2015 diagnosis that began with a sore throat that would not clear up.

Rockett said chemotherapy and radiation failed to stop his disease. He said doctors then raised the possibility of removing his tongue, and he recorded messages for his young children so they would know his voice.

"I would've most likely had a feeding tube," he said. His weight fell to 161 pounds during treatment. He chronicles the experience in his memoir, "Ghost Notes: My Life in Poison."

His account is one patient's story. It is not data from the JAMA Oncology study, and his treatment history differs from the regimen studied.

What comes next

The next test is whether quality-of-life data and a multicenter phase III trial confirm what this prospective series suggests. Until then, 30-Gy elective nodal dosing remains an approach with strong five-year cancer control numbers and no direct measure of patient-reported benefit.